PDCD1 and head and neck squamous cell carcinoma: Advanced research on the mechanisms of immune escape laid the basis for a new generation of targeted drugs for HNSCC, e.g., the anti-PD-1 nivolumab and pembrolizumab or anti-PD-L1 atezolizumab [111].